The Weight Loss Pill Bubble: Is Profitability a Pipe Dream? The recent share price drops for telehealth company Hims & Hers Health and pharmaceutical giant Novo Nordisk have raised eyebrows.
On the surface, these companies seem to be thriving due to rapid revenue growth and ambitious forecasts. However, profitability is proving elusive in the booming GLP 1 pill market.
Rising costs are a key concern for investors. Both Hims & Hers Health and Novo Nordisk have reported higher expenses as they expand into new markets and invest in branded GLP 1 drugs.